Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

291 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.
Dunachie SJ, Walther M, Vuola JM, Webster DP, Keating SM, Berthoud T, Andrews L, Bejon P, Poulton I, Butcher G, Watkins K, Sinden RE, Leach A, Moris P, Tornieporth N, Schneider J, Dubovsky F, Tierney E, Williams J, Heppner DG Jr, Gilbert SC, Cohen J, Hill AV. Dunachie SJ, et al. Among authors: sinden re. Vaccine. 2006 Apr 5;24(15):2850-9. doi: 10.1016/j.vaccine.2005.12.041. Epub 2006 Jan 6. Vaccine. 2006. PMID: 16434127 Clinical Trial.
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G, Vuola JM, Blanchard TJ, Gothard P, Watkins K, Hannan CM, Everaere S, Brown K, Kester KE, Cummings J, Williams J, Heppner DG, Pathan A, Flanagan K, Arulanantham N, Roberts MT, Roy M, Smith GL, Schneider J, Peto T, Sinden RE, Gilbert SC, Hill AV. McConkey SJ, et al. Among authors: sinden re. Nat Med. 2003 Jun;9(6):729-35. doi: 10.1038/nm881. Epub 2003 May 25. Nat Med. 2003. PMID: 12766765 Clinical Trial.
Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720.
Walther M, Dunachie S, Keating S, Vuola JM, Berthoud T, Schmidt A, Maier C, Andrews L, Andersen RF, Gilbert S, Poulton I, Webster D, Dubovsky F, Tierney E, Sarpotdar P, Correa S, Huntcooke A, Butcher G, Williams J, Sinden RE, Thornton GB, Hill AV. Walther M, et al. Among authors: sinden re. Vaccine. 2005 Jan 4;23(7):857-64. doi: 10.1016/j.vaccine.2004.08.020. Vaccine. 2005. PMID: 15603885 Clinical Trial.
Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein.
Walther M, Thompson FM, Dunachie S, Keating S, Todryk S, Berthoud T, Andrews L, Andersen RF, Moore A, Gilbert SC, Poulton I, Dubovsky F, Tierney E, Correa S, Huntcooke A, Butcher G, Williams J, Sinden RE, Hill AV. Walther M, et al. Among authors: sinden re. Infect Immun. 2006 May;74(5):2706-16. doi: 10.1128/IAI.74.5.2706-2716.2006. Infect Immun. 2006. PMID: 16622207 Free PMC article.
A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine.
Porter DW, Thompson FM, Berthoud TK, Hutchings CL, Andrews L, Biswas S, Poulton I, Prieur E, Correa S, Rowland R, Lang T, Williams J, Gilbert SC, Sinden RE, Todryk S, Hill AV. Porter DW, et al. Among authors: sinden re. Vaccine. 2011 Oct 6;29(43):7514-22. doi: 10.1016/j.vaccine.2011.03.083. Epub 2011 Apr 16. Vaccine. 2011. PMID: 21501642 Free PMC article. Clinical Trial.
Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.
Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, Laidlaw SM, McConkey SJ, Poulton I, Andrews L, Andersen RF, Bejon P, Butcher G, Sinden R, Skinner MA, Gilbert SC, Hill AV. Webster DP, et al. Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4836-41. doi: 10.1073/pnas.0406381102. Epub 2005 Mar 21. Proc Natl Acad Sci U S A. 2005. PMID: 15781866 Free PMC article. Clinical Trial.
Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial.
Thompson FM, Porter DW, Okitsu SL, Westerfeld N, Vogel D, Todryk S, Poulton I, Correa S, Hutchings C, Berthoud T, Dunachie S, Andrews L, Williams JL, Sinden R, Gilbert SC, Pluschke G, Zurbriggen R, Hill AV. Thompson FM, et al. PLoS One. 2008 Jan 30;3(1):e1493. doi: 10.1371/journal.pone.0001493. PLoS One. 2008. PMID: 18231580 Free PMC article. Clinical Trial.
A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.
Dunachie SJ, Walther M, Epstein JE, Keating S, Berthoud T, Andrews L, Andersen RF, Bejon P, Goonetilleke N, Poulton I, Webster DP, Butcher G, Watkins K, Sinden RE, Levine GL, Richie TL, Schneider J, Kaslow D, Gilbert SC, Carucci DJ, Hill AV. Dunachie SJ, et al. Among authors: sinden re. Infect Immun. 2006 Oct;74(10):5933-42. doi: 10.1128/IAI.00590-06. Infect Immun. 2006. PMID: 16988273 Free PMC article. Clinical Trial.
Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection.
Walther M, Tongren JE, Andrews L, Korbel D, King E, Fletcher H, Andersen RF, Bejon P, Thompson F, Dunachie SJ, Edele F, de Souza JB, Sinden RE, Gilbert SC, Riley EM, Hill AV. Walther M, et al. Among authors: sinden re. Immunity. 2005 Sep;23(3):287-96. doi: 10.1016/j.immuni.2005.08.006. Immunity. 2005. PMID: 16169501 Free article.
291 results